Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma

Shernan G. Holtan, Luis F. Porrata, David J. Inwards, Stephen Maxted Ansell, Ivana Micallef, Patrick Bruce Johnston, Mark R Litzow, Dennis A. Gastineau, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Autograft absolute lymphocyte count (A-ALC) is a prognostic factor for survival in non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (ASCT). An A-ALC is dependent upon the preaphaeresis absolute lymphocyte count (PA-ALC) at the time of aphaeresis. It was hypothesised that the time interval from last chemotherapy (TILC) to aphaeresis affects PA-ALC. One hundred and sixty consecutive NHL patients who underwent ASCT at the Mayo Clinic between 1996 and 2001 were evaluated. A strong correlation between TILC and PA-ALC (r = 0.67, P < 0.0001) was identified. Higher PA-ALC was observed in TILC ≥55 d compared with TILC <55 d [median: 7.0 vs. 3.8 × 109/l], P < 0.0001). TILC as a continuous variable was identified as a prognostic factor for overall survival (OS) [hazard ratio (HR) = 0.989, P < 0.01] and progression-free survival (PFS) (HR = 0.992, P < 0.0492). Median OS and PFS were longer in the TILC ≥55 d vs. TILC <55 d group (not reached vs. 21 months, P < 0.0008; 76 vs. 9 months, P < 0.0025, respectively). Multivariate analysis demonstrated TILC to be an independent prognostic indicator for OS and PFS. These findings suggest that the immune status of the host at the time of aphaeresis may predict survival after ASCT.

Original languageEnglish (US)
Pages (from-to)628-633
Number of pages6
JournalBritish Journal of Haematology
Volume133
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Lymphocytes
Lymphocyte Count
Drug Therapy
Survival
Blood Component Removal
Disease-Free Survival
Autografts
Multivariate Analysis

Keywords

  • Absolute lymphocyte count
  • Autologous stem cell transplantation
  • Chemotherapy
  • Non-Hodgkin lymphoma
  • Survival

ASJC Scopus subject areas

  • Hematology

Cite this

@article{1f1de46329f04c2697f066cf2173cae7,
title = "Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma",
abstract = "Autograft absolute lymphocyte count (A-ALC) is a prognostic factor for survival in non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (ASCT). An A-ALC is dependent upon the preaphaeresis absolute lymphocyte count (PA-ALC) at the time of aphaeresis. It was hypothesised that the time interval from last chemotherapy (TILC) to aphaeresis affects PA-ALC. One hundred and sixty consecutive NHL patients who underwent ASCT at the Mayo Clinic between 1996 and 2001 were evaluated. A strong correlation between TILC and PA-ALC (r = 0.67, P < 0.0001) was identified. Higher PA-ALC was observed in TILC ≥55 d compared with TILC <55 d [median: 7.0 vs. 3.8 × 109/l], P < 0.0001). TILC as a continuous variable was identified as a prognostic factor for overall survival (OS) [hazard ratio (HR) = 0.989, P < 0.01] and progression-free survival (PFS) (HR = 0.992, P < 0.0492). Median OS and PFS were longer in the TILC ≥55 d vs. TILC <55 d group (not reached vs. 21 months, P < 0.0008; 76 vs. 9 months, P < 0.0025, respectively). Multivariate analysis demonstrated TILC to be an independent prognostic indicator for OS and PFS. These findings suggest that the immune status of the host at the time of aphaeresis may predict survival after ASCT.",
keywords = "Absolute lymphocyte count, Autologous stem cell transplantation, Chemotherapy, Non-Hodgkin lymphoma, Survival",
author = "Holtan, {Shernan G.} and Porrata, {Luis F.} and Inwards, {David J.} and Ansell, {Stephen Maxted} and Ivana Micallef and Johnston, {Patrick Bruce} and Litzow, {Mark R} and Gastineau, {Dennis A.} and Markovic, {Svetomir Nenad}",
year = "2006",
month = "6",
doi = "10.1111/j.1365-2141.2006.06088.x",
language = "English (US)",
volume = "133",
pages = "628--633",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma

AU - Holtan, Shernan G.

AU - Porrata, Luis F.

AU - Inwards, David J.

AU - Ansell, Stephen Maxted

AU - Micallef, Ivana

AU - Johnston, Patrick Bruce

AU - Litzow, Mark R

AU - Gastineau, Dennis A.

AU - Markovic, Svetomir Nenad

PY - 2006/6

Y1 - 2006/6

N2 - Autograft absolute lymphocyte count (A-ALC) is a prognostic factor for survival in non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (ASCT). An A-ALC is dependent upon the preaphaeresis absolute lymphocyte count (PA-ALC) at the time of aphaeresis. It was hypothesised that the time interval from last chemotherapy (TILC) to aphaeresis affects PA-ALC. One hundred and sixty consecutive NHL patients who underwent ASCT at the Mayo Clinic between 1996 and 2001 were evaluated. A strong correlation between TILC and PA-ALC (r = 0.67, P < 0.0001) was identified. Higher PA-ALC was observed in TILC ≥55 d compared with TILC <55 d [median: 7.0 vs. 3.8 × 109/l], P < 0.0001). TILC as a continuous variable was identified as a prognostic factor for overall survival (OS) [hazard ratio (HR) = 0.989, P < 0.01] and progression-free survival (PFS) (HR = 0.992, P < 0.0492). Median OS and PFS were longer in the TILC ≥55 d vs. TILC <55 d group (not reached vs. 21 months, P < 0.0008; 76 vs. 9 months, P < 0.0025, respectively). Multivariate analysis demonstrated TILC to be an independent prognostic indicator for OS and PFS. These findings suggest that the immune status of the host at the time of aphaeresis may predict survival after ASCT.

AB - Autograft absolute lymphocyte count (A-ALC) is a prognostic factor for survival in non-Hodgkin lymphoma (NHL) after autologous stem cell transplantation (ASCT). An A-ALC is dependent upon the preaphaeresis absolute lymphocyte count (PA-ALC) at the time of aphaeresis. It was hypothesised that the time interval from last chemotherapy (TILC) to aphaeresis affects PA-ALC. One hundred and sixty consecutive NHL patients who underwent ASCT at the Mayo Clinic between 1996 and 2001 were evaluated. A strong correlation between TILC and PA-ALC (r = 0.67, P < 0.0001) was identified. Higher PA-ALC was observed in TILC ≥55 d compared with TILC <55 d [median: 7.0 vs. 3.8 × 109/l], P < 0.0001). TILC as a continuous variable was identified as a prognostic factor for overall survival (OS) [hazard ratio (HR) = 0.989, P < 0.01] and progression-free survival (PFS) (HR = 0.992, P < 0.0492). Median OS and PFS were longer in the TILC ≥55 d vs. TILC <55 d group (not reached vs. 21 months, P < 0.0008; 76 vs. 9 months, P < 0.0025, respectively). Multivariate analysis demonstrated TILC to be an independent prognostic indicator for OS and PFS. These findings suggest that the immune status of the host at the time of aphaeresis may predict survival after ASCT.

KW - Absolute lymphocyte count

KW - Autologous stem cell transplantation

KW - Chemotherapy

KW - Non-Hodgkin lymphoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33646672389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646672389&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2006.06088.x

DO - 10.1111/j.1365-2141.2006.06088.x

M3 - Article

C2 - 16704437

AN - SCOPUS:33646672389

VL - 133

SP - 628

EP - 633

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -